Safety and Efficacy of Cariprazine in Schizophrenia

Inclusion Criteria: * Patients who have provided informed consent prior to any study specific procedures * Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) * Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120 * Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 * Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG) Exclusion Criteria: * Patients with a DSM-IV-TR diagnosis of Schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder * Patients in their first episode of psychosis * Pregnant, breast-feeding, and/or planning to become pregnant and/or breastfeed during the study * Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders * Known or suspected borderline or antisocial personality disorder or other DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in this study * Substance abuse or dependence within the prior 3 months